Gratzl S, Rodriguez PJ, Goodwin BM, Baker C, Stucky N
Results from the first Phase III trial in obesity and overweight investigating the GIPR/GLP-1R co-agonist tirzepatide, which is currently approved for the treatment of type 2 diabetes and has resulted in marked body-weight reductions in type 2 diabetes [5, 43,44,45,46], were published in 2022 [28]
PlexusDx providers can evaluate your full medical record to recommend whether your weight loss goals are best served by optimized monotherapy, a dual-compound formulation, or a carefully managed dual-drug protocol
Regular check-ins : Stay in touch with your doctor, especially during the first few months of starting treatment
In conclusion, our study highlights the profound effects of ipamorelin on the upper GI tract and suggests that the compound may be of interest as a prokinetic agent to treat GI dysmotility, characterized by delayed gastric emptying and slow upper GI transit
Unopened compounded tirzepatide vials typically last until their beyond-use date, which ranges from 28 to 90 days from the date of compounding
